PB2122 VELCADITO. A PHASE II TRIAL WITH LOW DOSES OF BORTEZOMIB PLUS MELPHALAN AND PREDNISONE FOR ELDERLY PATIENTS (>75Y) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA | Publicación